IRIgor Radanović

Igor Radanović

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Igor Radanović has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • From Toad Venom to Drug Development: The Clinical Pharmacology of Mebufotenin (5-MeO-DMT) in Treatment-Resistant Depression

    by Robert Likić, Igor Radanović, Deni Rkman, Sanja Brnić, Gabriel Jacobs, Geert Jan Groeneveld

  • Open Access

    IL-2 mutein-engrafted antibody MHS552 selectively expands functional regulatory T cells in nonclinical models and healthy participants

    by Igor Radanović, Michael DiDonato, Anouk C. Meijs, David A. Schubert, Yaiza Diaz-De-Durana, Andrea Kiessling, Thierry Flandre, Hannah Morgan, Claudia Simonett, Justin McMullen, et al.

    Low-dose interleukin-2 (IL-2) shows potential for treating autoimmune disorders by expanding regulatory T cells (Treg), but therapeutic utility is limited by short half-life and off-target effects. Here, we describe the molecular design, nonclinical development, and first-in-human study of MHS552, an IL-2 mutein-engrafted antibody designed to selectively expand Treg via high-affinity IL-2 receptors. In vitro, MHS552 selectively induces IL-2 signaling in Treg from healthy donors and autoimmune patients. In cynomolgus monkeys, MHS552 produces dose-dependent Treg expansion, with modest increases in conventional T cells (Tconv) at higher doses. In a randomized, double-blind, placebo-controlled, single-ascending-dose trial in 60 healthy participants (EudraCT 2018-004233-33), evaluating safety and tolerability as the primary objective and pharmacokinetics as the secondary objective, intravenous and subcutaneous administration of MHS552 is well tolerated at lower doses and shows a predictable pharmacokinetic profile. However, a serious adverse event (SAE) is reported at the highest subcutaneous dose. Both administration routes result in dose-dependent Treg expansion, with up to 6-fold increase in total Treg and 60-fold increase in CD25hi subset, without significant conventional T cell activation. Exploratory analyses confirm selective Treg activation, with expanded Treg retaining their suppressive function ex vivo. These findings support IL-2-based therapeutics for autoimmune disorders, while the SAE highlights the need for careful safety evaluation.

  • Open Access

    Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early‐Phase Oncology Drug Development

    by Igor Radanović, Ingrid Tomljanović, Wieke H. Grievink, Diana R. Pereira, Michelle Osse, Peter van Balen, Maria J. Juachon, Marieke L. de Kam, Lisa Pagan, Manon A.A. Jansen, et al.

    Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions. We hypothesized that the intravenous LPS challenge model could be implemented in oncology drug studies in healthy participants to evaluate in vivo pharmacodynamics of new drugs. This open‐label study included 13 healthy males who received a single intravenous dose of 1 or 2 ng/kg LPS. Blood and bone marrow samples were collected pre‐ and post‐LPS for bulk RNA sequencing, multiplex cytokine measurements, immunophenotyping, and immunohistochemistry of bone marrow biopsies. Differentially expressed genes were integrated with the OpenTargets Platform and the COSMIC database to assess their tractability and relation to cancer hallmarks. The LPS challenge and bone marrow sampling were safe and well tolerated. In peripheral blood, LPS induced a rapid, transient inflammatory response, with myeloid cell activation and enrichment of inflammation‐related pathways. Conversely, bone marrow showed an attenuated cellular response and activation of hematopoietic and cell cycle‐related transcriptional programs. We identified 91 LPS‐induced oncology‐relevant targets in blood and 24 targets in bone marrow. The oncogenic transcription factor MYC was upregulated in the bone marrow, which was confirmed at the protein level by a dose‐dependent increase in c‐Myc expression. Our findings highlight the potential of immune challenges in healthy participants to pharmacodynamically profile novel oncology agents, with the aim of generating early pharmacological data ahead of pivotal clinical trials in cancer patients.

  • Open Access

    Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial

    by Pepijn Eijsvogel, Pinaki Misra, Luis Concha-Marambio, Justin D. Boyd, Shuang Ding, Lauren Fedor, Yueh-Ting Hsieh, Yu Shuang Sun, Madeline M. Vroom, Carly M. Farris, et al.

    Investigational therapeutics that target toxic species of α-synuclein (αSyn) aim to slow down or halt disease progression in patients with Parkinson’s disease (PD). Here this 44-week, randomized, placebo-controlled, double-blind, single-center phase 1 study investigated safety, tolerability and immunogenicity of UB-312, an active immunotherapeutic targeting pathological αSyn, in patients with PD. The primary outcome measures were adverse event frequency and change in anti-αSyn antibody titers in blood and cerebrospinal fluid (CSF). Exploratory outcomes were changes in clinical scales and biomarker-based target engagement as measured by seed amplification assays. Twenty patients were randomized 7:3 (UB-312:placebo) into 300/100/100 μg or 300/300/300 μg (weeks 1, 5 and 13) intramuscular prime-boost dose groups. Safety was similar across groups; adverse events were mostly mild and transient. Two patients experienced three serious adverse events in total, one possibly treatment related; all resolved without sequalae. Anti-αSyn antibodies in serum from 12/13 and CSF from 5/13 patients who received three UB-312 doses confirmed immunogenicity. Mean serum titers (in log-dilution factor) increased from baseline by 1.398 and 1.354, and peaked at week 29 at 2.520 and 2.133, for 300/100/100 μg and 300/300/300 μg, respectively. CSF titers were 0 at baseline and were 0.182 and 0.032 at week 21, respectively. Exploratory analyses showed no statistical differences in clinical scales but a significant reduction of αSyn seeds in CSF of a subset of UB-312-treated patients. These data support further UB-312 development. ClinicalTrials.gov:NCT04075318.


  • Open Access

    Spotlight Commentary: Importance of dose redefining in the process of drug repurposing

    by Igor Radanovic, Robert Likic, Geert Jan Groeneveld


  • Open Access

    Fas receptor induces apoptosis of synovial bone and cartilage progenitor populations and promotes bone loss in antigen‐induced arthritis

    by Elvira Lazić Mosler, Nina Lukač, Darja Flegar, Martina Fadljević, Igor Radanović, Hrvoje Cvija, Tomislav Kelava, Sanja Ivčević, Alan Šućur, Antonio Markotić, et al.

    Rheumatoid arthritis (RA) is an inflammatory joint disease that eventually leads to permanent bone and cartilage destruction. Fas has already been established as the regulator of inflammation in RA, but its role in bone formation under arthritic conditions is not completely defined. The aim of this study was to assess the effect of Fas inactivation on the bone damage during murine antigen‐induced arthritis. Subchondral bone of wild‐type (WT) and Fas‐knockout (Fas −/− ) mice was evaluated by histomorphometry and microcomputerized tomography. Proportions of synovial bone and cartilage progenitors were assessed by flow cytometry. Synovial bone and cartilage progenitors were purified by fluorescence‐activated cell sorting and expression of Fas and Fas‐induced apoptosis were analyzed in vitro . Results showed that Fas −/− mice developed attenuated arthritis characterized by preserved epiphyseal bone and cartilage. A proportion of the earliest CD200 + bone and cartilage progenitors was reduced in WT mice with arthritis and was unaltered in Fas −/− mice. During osteoblastic differentiation in vitro , CD200 + cells express the highest levels of Fas and are removed by Fas ligation. These results suggest that Fas‐induced apoptosis of early CD200 + osteoprogenitor population represents potential mechanism underlying the impaired bone formation in arthritis, so their preservation may represent the bone‐protective mechanism during arthritis.—Lazić Mosler, E., Lukač, N., Flegar, D., Fadljević, M., Radanović, I., Cvija, H., Kelava, T., Ivčević, S., Šućur, A., Markotić, A., Katavić, V., Marušić, A., Grčević, D., Kovačić, N. Fas receptor induces apoptosis of synovial bone and cartilage progenitor populations and promotes bone loss in antigen‐induced arthritis. FASEB J. 33, 3330–3342 (2019). www.fasebj.org


  • Top Cited Papers

    Opportunities for Use of Blockchain Technology in Medicine

    by Igor Radanović, Robert Likić

    Blockchain technology is a decentralized database that stores a registry of assets and transactions across a peer-to-peer computer network, which is secured through cryptography, and over time, its history gets locked in blocks of data that are cryptographically linked together and secured. So far, there have been use cases of this technology for cryptocurrencies, digital contracts, financial and public records, and property ownership. It is expected that future uses will expand into medicine, science, education, intellectual property, and supply chain management. Likely applications in the field of medicine could include electronic health records, health insurance, biomedical research, drug supply and procurement processes, and medical education. Utilization of blockchain is not without its weaknesses and currently, this technology is extremely immature and lacks public or even expert knowledge, making it hard to have a clear strategic vision of its true future potential. Presently, there are issues with scalability, security of smart contracts, and user adoption. Nevertheless, with capital investments into blockchain technology projected to reach US$400 million in 2019, health professionals and decision makers should be aware of the transformative potential that blockchain technology offers for healthcare organizations and medical practice.


  • Chronic meningoencephalitis caused by Echo virus 6 in a patient with common variable immunodeficiency

    by Igor Radanović, Deni Rkman, Paulo Zekan, Marko Kutleša, Bruno Baršić

    Chronic enteroviral meningoencephalitis, most commonly caused by echoviruses, can particularly be seen in agammaglobulinemic patients. In spite of the fact that no specific treatment for enteroviral infections exists, pleconaril is an antiviral drug reported to be efficient against enteroviral infections in infants and adults. We present a case of a 42-year-old male, previously diagnosed with common variable immunodeficiency, who presented with severe chronic meningoencephalitis caused by Echo virus 6 and was successfully treated with pleconaril. Enteroviruses usually cause mild symptoms, but some strains can cause life-threatening conditions especially in immunocompromised patients. Although pleconaril production is unprofitable due to the rarity of severe disease, our effective treatment should encourage further availability of pleconaril.